diabetestalk.net

Tandem T Slim Pump

Share on facebook

Tandem Touts Adoption Of Cgm Update To T:slim X2 Insulin Pump

Tandem touts adoption of CGM update to t:slim X2 insulin pump Last month, Tandem Diabetes Care (NSDQ: TNDM ) announced that the FDA approved its t:slim X2 insulin pump integrated with Dexcom s (NSDQ: DXCM ) G5 mobile continuous glucose monitor. The San Diego, Calif.-based company made the software available to its current t:slim X2 pump users at no additional cost, enabling them to add CGM-integration to their existing devices. Today, the company reported that one-third of t:slim X2 pump users have updated their pumps to integrate Dexcoms glucose monitoring tech. Of those who have taken Tandem up on the software update, more than 85% said they were satisfied or extremely satisfied with the process, the company said. We are demonstrating our continued commitment to customer care by providing a simple, efficient and cost-effective way for people to keep up with our latest technology, president & CEO Kim Blickenstaff said in prepared remarks. We are the first and only company to offer its customers the ability to remotely update their insulin pump software using their personal computer. The rapid uptake and high satisfaction scores weve received since launch further validate our stra Continue reading >>

Share on facebook

Popular Questions

  1. Thomas

    How difficult is college life for a T1?
    I am hoping Tandem has the Third Update for its t:slim X2 from its published pipeline which is the Hybrid Closed Loop working with the Dexcom. The launch goal is late 2018.
    Tandem has today updated its “Pipeline”.
    October 12, 2017
    Tandem has reiterated the pivotal study for its first generation Automated Insulin Delivery (AID) called the Predictive Low Glucose Suspend (PLGS) is anticipated to conclude by the end of 2017. The PLGS will run on the Tandem t:slim X2 using sensor data from the Dexcom G5. Based upon FDA approval, Tandem continues to have the goal to launch the PLGS via remote update in the summer of 2018.
    Tandem’s second generation AID called the Hybrid Closed Loop (HCL) will also run on the X2 using technology from TypeZero and using sensor data from the Dexcom G6. This system will both increase and decrease basal insulin based on predicted BG as well as deliver automated correction boluses. Tandem has pushed this out and the current goal for this is the first half of 2019.
    Tandem also has under development the t:sport. It is expected to be half the size of the t:slim and “designed for people who seek even greater discretion and flexibility with the use of their insulin pump”. No date is set for this.
    Tandem is planning to launch a first generation mobile application in 2018. This will connect via Bluetooth to the pump. Initially it sounds like it will simply upload the pump information to the Tandem cloud (t:connect). A future generation will support pump-control capabilities however possible not for the t:slim X2 but only for newer pumps currently under development. So this sounds to be a number of years down the road. R&D. Don’t hold your breath.

    A few company / business points:
    Tandem has shipped more than 60,000 insulin pumps since their initial launch in August 2012.
    Tandem expects to have 11% of the USA insulin pump market at the end of 2017.
    Tandem believes they can be profitable when they reach 15% USA market share for which their goal is 2019.
    Tandem is potentially planning to launch internationally in 2018.

  2. Eric

    How difficult is college life for a T1?
    Tandem also has under development the t:sport. It is expected to be half the size of the t:slim and “designed for people who seek even greater discretion and flexibility with the use of their insulin pump”. No date is set for this.
    I heard about this a year ago from a Tandem rep, and my understanding at the time was that the t:sport would be tubeless and compete with the omnipod in the tubeless pump space. That is something I would be interested in. But if it is just a smaller version of the tubed pump, it would mean nothing to me personally.

    Any idea about that, Thomas?

  3. Thomas

    My first thought was: vaporware? lol. But then I considered it a bit more.
    I also thought it had an Omnipod sound about it. I mentioned it as it sounded mildly interesting and was the first I had heard of it. Also as this was direct and specific from the company and not just internet chatter.
    I agree with you Eric. Just a smaller version of the t:slim pump doesn’t really make sense and would seem to have little commercial value. Already Tandem advertises the t:slim as the smallest pump or something like that. So, there would have to be significant differences between the t:sport and the t:slim. Being tubeless does seem to be an obvious assumption. Probably this is going to have to get further down the R&D process before we get additional details.
    If a company has actual products out (such as Tandem obviously does) then it actually is nice for them to also mention what they may have going on in their R&D which may or may not ever see the light of day. The flip side of that was Animas who (as I recall) seemed to have a policy of never saying anything about what they might be doing and blamed it on the FDA for not being able to talk which was a load of bull. Maybe the Tandem t:sport will show up in a few years and maybe not - but nice to get an idea of things they are kicking around.

    There were a couple reasons we switched from the Animas Ping to the Tandem t:slim X2. Among those, was the failure of Animas to provide any public details of what they might be working on. This was as compared to Tandem which has their “Pipeline” of t:slim X2 updates published on their website.

  4. -> Continue reading
read more close

Related Articles

Popular Articles

More in insulin